Quantcast
Last updated on April 25, 2014 at 1:22 EDT

Latest Eribulin Stories

2014-02-27 08:30:00

Patient Recruitment Now Underway at Treatment Centers Across the United States WOODCLIFF LAKE, N.J., Feb. 27, 2014 /PRNewswire/ -- Eisai Inc. today announced the start of a large, randomized Phase 3 trial to compare the efficacy, safety and tolerability of eribulin mesylate to standard weekly paclitaxel as a first- or second- line treatment for HER2-negative locally recurrent or metastatic breast cancer (MBC). Recruitment is currently active for this multicenter study, conducted in...

2013-12-04 08:29:53

WOODCLIFF LAKE, N.J., Dec. 4, 2013 /PRNewswire/ -- Eisai Inc. announced today that five abstracts highlighting new study results will be presented during the 2013 San Antonio Breast Cancer Symposium. The meeting will be held December 10-14, 2013 at the Henry B. Gonzalez Convention Center in San Antonio, TX. (Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO ) The studies highlight Eisai's current and ongoing clinical research efforts with eribulin mesylate, and reinforce the...

2013-11-17 20:21:21

HATFIELD, England, November 18, 2013 /PRNewswire/ -- Eisai announces today that Halaven(R) (eribulin) will be marketed in selected countries within the Middle East region through a new partnership between Eisai EMEA (Europe, the Middle East, Africa, Russia and Oceania) and NewBridge Pharmaceuticals. Eribulin is indicated for the treatment of locally advanced or metastatic breast cancer, which has progressed after at least two chemotherapeutic regimens for advanced disease....

2013-06-13 16:39:12

Subgroup analyses from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate, with capecitabine, a standard chemotherapy medication in women with previously treated metastatic breast cancer, showed increased benefit among women sharing certain traits. Specifically, these analyses demonstrated a greater potential benefit in certain subsets of patients with metastatic breast cancer. This analysis was presented by Peter A. Kaufman, M.D., during the 2013 ASCO...

2013-05-16 16:25:39

WOODCLIFF LAKE, N.J., May 16, 2013 /PRNewswire/ -- Eisai Inc. announced today that nine abstracts highlighting new study results in melanoma, breast and endometrial cancer will be presented during the 49(th) Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago from May 31 - June 4, 2013. (Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO ) "These studies reinforce Eisai's strong and growing commitment to oncology, particularly to...

2013-03-05 04:21:08

PARSIPPANY, N.J., March 5, 2013 /PRNewswire/ -- DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM (NYSE/Euronext: DSM KON), today announced the signing of a 3 year master supply agreement with Eisai Inc., based in Woodcliff Lake, NJ, USA, for the production of sterile products. The agreement covers the production of eribulin mesylate as well as other developmental drugs. Alexander Wessels, President and CEO of DSM Pharmaceutical Products,...

2013-01-29 12:27:11

BURLINGTON, Mass., Jan. 29, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, although interviewed oncologists in the United States and Europe would like to see a future of personalized medicine targeting different soft tissue sarcoma subtypes, they believe that it is in fact novel chemotherapies that hold the most near-term promise for improving outcomes in this highly fragmented...

2012-12-07 08:24:49

SAN ANTONIO, Dec. 7, 2012 /PRNewswire/ -- Results from the first large, global Phase III study of Halaven(®) (eribulin mesylate) Injection in patients with early-stage metastatic breast cancer were presented today during the 2012 CTRC-AACR San Antonio Breast Cancer Symposium. (Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO ) The 1,102-patient, open-label, multi-center study compared Halaven versus capecitabine (Xeloda(®)) in women with locally advanced or metastatic...

2012-11-28 12:26:49

WOODCLIFF LAKE, N.J., Nov. 28, 2012 /PRNewswire/ -- Eisai Inc. announced today that six abstracts highlighting new study results will be presented during the 2012 CTRC-AACR San Antonio Breast Cancer Symposium. The meeting will be held December 4-8, 2012 at the Henry B. Gonzalez Convention Center in San Antonio, TX. (Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO ) These studies highlight Eisai's current and ongoing clinical research efforts with Halaven(®) (eribulin...

2012-08-17 06:06:46

“Hints” for longer survival only in specific patients / Greater harm cannot be excluded Eribulin (trade name: Halaven®) was approved in March 2011 for women with locally advanced or metastasizing breast cancer in whom the disease has progressed despite prior drug therapy. In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products” (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined...